Interchangeability on formulary coverage of adalimumab biosimilars in Medicare part D
Journal of the American Academy of Dermatology · 2026-08 · 95 (2) · 540-542
DOI: 10.1016/j.jaad.2026.04.035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-08. Verfasst von Alina S Feng und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of California San Francisco, San Francisco, California. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, University of California San Francisco, San Francisco, California.
- Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California.
- Department of Dermatology, University of California San Francisco, San Francisco, California. Electronic address: wilson.liao@ucsf.edu.
Zitieren
APA
Feng, A. S., Liang, R., & Liao, W. (2026). Interchangeability on formulary coverage of adalimumab biosimilars in Medicare part D. Journal of the American Academy of Dermatology, 95(2), 540-542. https://doi.org/10.1016/j.jaad.2026.04.035
Vancouver
Feng AS, Liang R, Liao W. Interchangeability on formulary coverage of adalimumab biosimilars in Medicare part D. Journal of the American Academy of Dermatology. 2026;95(2):540-542. doi:10.1016/j.jaad.2026.04.035
BibTeX
@article{Feng2026,
author = {Feng, Alina S and Liang, Richard and Liao, Wilson},
title = {Interchangeability on formulary coverage of adalimumab biosimilars in Medicare part D},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {2},
pages = {540--542},
doi = {10.1016/j.jaad.2026.04.035}
}
EUVIMED